Skip to main content
. 2006 Mar 9;116(4):1025–1036. doi: 10.1172/JCI23792

Figure 5. Therapeutic effect of anti-CD137 mAb on airway remodeling.

Figure 5

BALB/c mice were immunized with OVA on day 1 and challenged with OVA intranasally several times according to reversal protocol II (Figure 1), described in Methods. After application of anti-CD137 mAb or control mAb on day 32, mice were challenged again with OVA on days 39–41. On day 43, mice were sacrificed. (A) MSB-stained lung tissues (magnification, ×400) from BALB/c mice revealed increased peribronchiolar ECM deposition, which was reduced by anti-CD137 mAb. (B) For quantification of ECM deposition, digital photographs of 4 bronchioles per tissue section were taken and analyzed with a computer-based image-analyzing program, demonstrating the protective effect of anti-CD137 mAb. (C) Total lung collagen was increased in OVA-immunized mice compared with control animals. This effect was partly abrogated (62%) by anti-CD137 mAb application. *P < 0.05, OVA plus anti-CD137 mAb versus OVA plus control antibody by Student’s t test. n ≥ 8 animals per group; data are expressed as mean ± SEM from 2 independent experiments.